143 completed, 49 terminated, 27 recruiting, 25 active not recruiting. 270 Phase 1, 80 Phase 2.
Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer (Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Rebecca Arend | 24 | 2026-09-01 | 2026-10-15 |
| IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Sacituzumab govitecan monotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 19 | 2026-07-01 | 2026-06-30 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-02-04 | 2026-03-18 |
| Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer AZD5335, Itraconazole - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Recruiting | AstraZeneca | 32 | 2026-01-26 | 2026-09-29 |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers | Phase 1 / Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 60 | 2025-12-10 | 2026-07-13 |
| Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer Cirtuvivint, Olaparib - Endometrioid Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Recruiting | University of Colorado, Denver | 50 | 2025-12-08 | 2026-07-24 |
| Surgery for Relapsed Ovarian Cancer in Precision surgery/chemotherapy, Iparomlimab/Tuvonralimab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 33 | 2025-07-01 | 2025-06-27 |
| SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer SCT-001 CAR-T cells - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 24 | 2025-06-01 | 2025-02-26 |
| The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer Olaparib - Ovarian Cancer, Epithelial Cancer | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 55 | 2025-05-01 | 2026-03-10 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors SIM0505 for injection - Advanced Solid Tumors, Platinum Resistant Ovarian Cancer | Phase 1 | Recruiting | NextCure, Inc. | 738 | 2025-02-26 | 2026-08-17 |
| A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer BAT8006 for Injection - Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Withdrawn | Bio-Thera Solutions | 2025-01-31 | 2026-01-07 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers 27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2024-08-06 | 2026-02-03 |
| Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer FT536, Fludarabine, CY - Gynecologic Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 3 | 2024-07-11 | 2026-04-02 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
Showing 20 of 270. Sign in to see all of them.
Fallopian Tube Neoplasms (268) · Ovarian Neoplasms (205) · Carcinoma, Ovarian Epithelial (100) · Endometrial Neoplasms (50) · Breast Neoplasms (35) · Uterine Cervical Neoplasms (27) · Carcinoma, Non-Small-Cell Lung (25) · Triple Negative Breast Neoplasms (24) · Neoplasms (22) · Carcinoma, Renal Cell (20) · Stomach Neoplasms (19) · Pancreatic Neoplasms (18) · Recurrence (17) · Brenner Tumor (15) · Carcinoma, Hepatocellular (14)
Adnexal Diseases (270) · Female Urogenital Diseases (270) · Female Urogenital Diseases and Pregnancy Complications (270) · Genital Diseases (270) · Genital Diseases, Female (270) · Urogenital Diseases (270) · Neoplasms by Site (268) · Urogenital Neoplasms (268) · Genital Neoplasms, Female (265) · Endocrine System Diseases (250) · Endocrine Gland Neoplasms (249) · Gonadal Disorders (249) · Neoplasms (247) · Ovarian Diseases (246)
Carboplatin (63) · Paclitaxel (46) · Bevacizumab (22) · liposomal doxorubicin (20) · Cyclophosphamide (19) · Gemcitabine (18) · Taxes (15) · Topotecan (15) · pembrolizumab (15) · Cisplatin (13) · Docetaxel (9) · olaparib (9) · Magnetic Resonance Spectroscopy (8) · Specimen Handling (8) · Biopsy (7)
National Cancer Institute (NCI) (29) · M.D. Anderson Cancer Center (15) · Gynecologic Oncology Group (11) · Memorial Sloan Kettering Cancer Center (10) · Roswell Park Cancer Institute (9) · Masonic Cancer Center, University of Minnesota (7) · City of Hope Medical Center (5) · Regeneron Pharmaceuticals (5) · Abramson Cancer Center at Penn Medicine (4) · Mayo Clinic (4) · AstraZeneca (3) · Celldex Therapeutics (3) · Dana-Farber Cancer Institute (3) · Fox Chase Cancer Center (3) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (3)
United States (223) · Canada (21) · Spain (18) · Belgium (14) · Australia (13) · United Kingdom (12) · France (10) · China (8) · Germany (8) · Netherlands (8) · South Korea (7) · Italy (5) · Japan (4) · Denmark (3) · Ireland (3)
Paul Sabbatini, MD (6) · Kunle Odunsi (5) · Emese Zsiros, MD (3) · Levi S. Downs, MD (3) · Peter G. Rose, MD (3) · Shannon N Westin (3) · Amir A Jazaeri (2) · Andrea E Wahner Hendrickson (2) · Don Dizon (2) · Floor Backes, MD (2) · Gina Martina-Smaldone, MD (2) · Joyce F Liu (2) · Lilie L Lin (2)
PMID 16394300, PMID 19949018, PMID 22002018, PMID 23810467, PMID 25218906, PMID 32379297, PMID 36459691, PMID 36608308, PMID 37185961, PMID 40132910, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11181662, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12082455, PMID 12082456, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 14701743, PMID 15131031, PMID 15327776, PMID 15367671, PMID 15665856, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16135465, PMID 16150481, PMID 16239238, PMID 16357170, PMID 16368439, PMID 16412499, PMID 16912188, PMID 16946210, PMID 16959305, PMID 17714938, PMID 17910981, PMID 18024865, PMID 18191187, PMID 18268546, PMID 18451240, PMID 18955455, PMID 19049966
U10CA027469 (11), P30CA016056 (6), U10CA180868 (6), UM1CA186709 (6), 2023 (5), P30CA006516 (3), P50CA083639 (3), U01CA076576 (3), 2019 (2), N01CM62204 (2), P01CA111412 (2), P30CA006927 (2), P30CA013330 (2), P30CA016087 (2), P30CA033572 (2)